Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis ...

Bydureon pen AstraZeneca announced data from a 10-week Phase 4 randomized, controlled, double-blind study assessing the quality of glucose control with Bydureon (exenatide extended-release) for ...

A new class of diabetes medications is masking the potentially dangerous condition of ketoacidosis at the time of surgery. Testing for acid load in the blood of diabetes sufferers who are taking ...

The role of insulin (IN) on cerebral glucose(glu) metabolism in newborn mammals is unknown. We employed the euglycemic hyperinsulinemic (HI) clamp (N=36) alone or combined with tissue 2-deoxy [14 C] ...

Improving safety and adherence of oral chemotherapy. This is an ASCO Meeting Abstract from the 2018 Quality Care Symposium. This abstract does not include a full text component.

A total of 1321 healthy, normotensive Korean men, aged 20–78 years, with a fasting plasma glucose level <100 mg/dl. Height, weight, and waist; systolic blood pressure (SBP); diastolic blood pressures ...

Table 1 presents nine patients with 13 episodes of euDKA or ketosis in the setting of treatment with SGLT-2 inhibitors. Among these patients, three had repeat episodes of ketosis on rechallenge. None ...